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Achromatopsia type 2 (ACHM2) is a severe, inherited eye disease caused by mutations
in the CNGA3 gene encoding the α subunit of the cone photoreceptor cyclic
nucleotide-gated (CNG) channel. Patients suffer from strongly impaired daylight vision,
photophobia, nystagmus, and lack of color discrimination. We have previously shown
in the Cnga3 knockout (KO) mouse model of ACHM2 that gene supplementation
therapy is effective in rescuing cone function and morphology and delaying cone
degeneration. In our preclinical approach, we use recombinant adeno-associated virus
(AAV) vector-mediated gene transfer to express the murine Cnga3 gene under control
of the mouse blue opsin promoter. Here, we provide novel data on the efficiency and
permanence of such gene supplementation therapy in Cnga3 KO mice. Specifically, we
compare the influence of two different AAV vector capsids, AAV2/5 (Y719F) and AAV2/8
(Y733F), on restoration of cone function, and assess the effect of age at time of treatment
on the long-term outcome. The evaluation included in vivo analysis of retinal function
using electroretinography (ERG) and immunohistochemical analysis of vector-driven
Cnga3 transgene expression. We found that both vector capsid serotypes led to a
comparable rescue of cone function over the observation period between 4 weeks and 3
months post treatment. In addition, a clear therapeutic effect was present in mice treated
at 2 weeks of age as well as in mice treated at 3 months of age at the first assessment
at 4 weeks after treatment. Importantly, the effect extended in both cases over the entire
observation period of 12 months post treatment. However, the average ERG amplitude
levels differed between the two groups, suggesting a role of the absolute age, or possibly,
the associated state of the degeneration, on the achievable outcome. In summary, we
found that the therapeutic time window of opportunity for AAV-mediated Cnga3 gene
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supplementation therapy in the Cnga3 KO mouse model extends at least to an age
of 3 months, but is presumably limited by the condition, number and topographical
distribution of remaining cones at the time of treatment. No impact of the choice of capsid
on the therapeutic success was detected.
Keywords: AAV vector, gene therapy, CNGA3, achromatopsia, subretinal delivery, cone function restoration,
non-invasive diagnostic techniques, photoreceptor cells
INTRODUCTION
Achromatopsia (ACHM) is an autosomal recessively inherited
disorder affecting cone-mediated vision with an overall
prevalence of 1:30,000 (Poloschek and Kohl, 2010; Zobor
et al., 2015; Aboshiha et al., 2016). Patients with ACHM suffer
from severely impaired daylight vision, poor visual acuity,
photophobia, nystagmus, and lack of the ability to discriminate
colors (Biel and Michalakis, 2007). In addition to these
functional defects, ACHM patients present varying degrees of
cone photoreceptor degeneration. Currently six genes have been
linked to ACHM: ATF6 (activating transcription factor 6A; MIM
605537) (Kohl et al., 2015), CNGA3 (cyclic nucleotide–gated
cation channel α3; MIM 600053; ACHM2, MIM 216900) (Kohl
et al., 1998), CNGB3 (cyclic nucleotide–gated cation channel β3,
MIM 605080; ACHM3, MIM 262300) (Kohl et al., 2000; Sundin
et al., 2000), GNAT2 (guanine nucleotide–binding protein G(t)
subunit α2; ACHM4, MIM 139340) (Aligianis et al., 2002; Kohl
et al., 2002), PDE6C (cone cyclic GMP–specific 3′,5′ cyclic
phosphodiesterase α; ACHM5, MIM 600827 and COD4, MIM
613093) (Chang et al., 2009; Thiadens et al., 2009), and PDE6H
(cone cyclic GMP–specific phosphodiesterase γ; MIM 601190;
ACHM6 or RCD3A, MIM 610024) (Kohl et al., 2012). Three in
four patients carry mutations in CNGA3 or CNGB3, the genes
encoding the two subunits of the cyclic nucleotide-gated (CNG)
channel in cone photoreceptors (Kohl et al., 2005; Poloschek
and Kohl, 2010). The cone photoreceptor CNG channel is an
essential component of the visual transduction cascade and
translates light-dependent changes in the second messenger
cyclic guanosine monophosphate (cGMP) into electrical activity,
which in turn controls the release of neurotransmitters at the
synapses to secondary neurons. The cone CNG channel forms
a heterotetrameric complex composed of three CNGA3 and
one CNGB3 subunits (Shuart et al., 2011). The absence of CNG
channels in cone photoreceptor outer segments of ACHM
patients results in complete lack of cone photoreceptor function.
We have previously shown that a genetic inactivation of
Cnga3 in mice—like in human patients—leads to selective loss
of cone mediated light responses (Biel et al., 1999) accompanied
by morphological, structural, and molecular changes, and finally
results in cone cell death (Michalakis et al., 2005). The
pathophysiological changes include a disorganization of cone
membrane structure, mislocalization of cone opsins, down-
regulation of outer segment proteins and degeneration of cones
which progresses in a ventral to dorsal gradient with the fastest
rate of degeneration in the ventral retina of Cnga3 KOmice.
Currently, no treatment for ACHM is available, but several
translational research programs aim at the development of
curative treatments for ACHM (Michalakis et al., 2017). As
described above, ACHM is a result of loss-of-function or
missense mutations in certain genes and is inherited in an
autosomal recessive manner. Therefore, gene supplementation
therapy providing healthy copies of affected genes is a promising
approach to cure ACHM. Over the past years, retinal application
of AAVs has proven to be safe and efficient in various disease
models (Schön et al., 2013; Petit et al., 2016; Michalakis
et al., 2017). Current clinical trials include RPE65-linked LCA,
choroideremia and achromatopsia (Petit et al., 2016; Scholl et al.,
2016).
Focusing on CNGA3-linked ACHM, we have previously
demonstrated restoration of visual function following adeno-
associated virus (AAV) vector-mediated gene supplementation
therapy in the Cnga3 KO mouse model (Michalakis et al.,
2010). The treatment resulted in reestablishment of regular CNG
ion channel complexes in cone outer segments. In addition,
normal cGMP levels were restored, which enabled the previously
unresponsive cones to gain the ability to generate specific light
responses.
Here, we provide novel data on further aspects of the
therapeutic outcome beyond the initial proof-of-concept studies.
Particular interest was given to intermediate and long-term
follow-up of the treatment effect in Cnga3 KO mice and the use
of different AAV serotypes.
MATERIALS AND METHODS
Animals and Ethics Statement
Animals were housed under standard white cyclic light (200
lux, 12 h dark-light periods), had free access to food and water,
and were used irrespective of gender. All procedures involving
animals were performed in accordance with the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
The study and the protocol were approved by the competent
local authority, Regierungspräsidium Tübingen, basing on the
assessment by the appointed regional ethics board.
Cloning and Production of AAV Vectors
Cloning and mutagenesis were performed by standard
techniques. All sequence manipulations were confirmed by
sequencing. Single-strand genome AAV2/5 Y719F (Michalakis
et al., 2010) or AAV2/8 Y733F (Koch et al., 2012) pseudotyped
AAV2 vectors expressing mouse Cnga3 cDNA (Michalakis et al.,
2010) under control of a 0.5 kb mouse blue (S) opsin (Michalakis
et al., 2010) were produced as described recently (Becirovic et al.,
2016). Physical titers (in vector genomes/µl) were determined
by quantitative PCR on a LightCycler 480 (Roche Applied
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Science, Mannheim, Germany) using KAPPA SYBR FAST kit
(Peqlab, Erlangen, Germany) and the following primer set:
WPREF: 5′-AGTTGTGGCCCGTTGTCAGG-3′ and WPRER:
5′-AGTTCCGCCGTGGCAATAGG-3′.
Subretinal AAV Injections
A detailed protocol for optimized subretinal injection technique
was described previously (Mühlfriedel et al., 2013). In brief, mice
were anesthetized by subcutaneous injection of ketamine (66.7
mg/kg) and xylazine (11.7 mg/kg), and their pupils were dilated
with tropicamide eye drops (Mydriaticum Stulln; Pharma Stulln,
Germany). Young mice (postnatal 14 days) received a single
subretinal injection of 1 µl of AAV particles (∼5 × 109 total
vector genomes) at the ventral part, whereas in aged animals
(from postnatal month one), due to the ventral-dorsal gradient of
cone degeneration, the viral particles were applied at the dorsal
part. The injection was performed free hand under a surgical
microscope (Carl Zeiss, Germany) using a NanoFil injection kit
(WPI, Germany) equipped with a 34 gauge beveled needle. In the
experimental design, one eye was treated whereas the untreated
eye served as the untouched control. Special care was taken to
avoid damage of the lens. After injection, in vivo imaging was
performed (described in next section). Animals were placed on a
warming blanket and eye ointment (Vidisic R©, Dr. Mann Pharma,
Berlin, Germany) was applied to the corneas to prevent drying
while the animals recovered from anesthesia. In addition, an
antibiotic eye ointment was applied two times daily for 48 h
(Dexamytrex R©, Bausch & Lomb, Berlin, Germany).
Qualitative Analysis by In vivo Imaging
Techniques
The quality of the injection and retinal morphology were
examined immediately after subretinal injection using confocal
scanning laser ophthalmoscopy (cSLO) and spectral domain
optical coherence tomography (SD-OCT). The cSLO procedure
was reported previously (Seeliger et al., 2005). For consecutive
examinations at later time points, mice were anesthetized and
pupils were dilated as described in section “subretinal AAV
injections.” cSLO images were obtained with a Heidelberg Retina
Angiograph (HRA I) at 10 and 20◦ field of view. Two different
imaging modalities were used to visualize the retina: (1) 514 nm
laser excitation, red free imaging mode, (2) and 830 nm laser
excitation, infrared imaging mode. SD-OCTs were performed
using a Spectralis TM HRA + OCT device from Heidelberg
Engineering (Fischer et al., 2009; Huber et al., 2009). Imaging
data were analyzed using the software package Eye Explorer
version 3.2.1.0 fromHeidelberg Engineering. Resulting data were
exported as 24 bit color image files and processed in Adobe
Photoshop CS3 (Adobe Systems, San Jose, CA, USA) (Garcia
Garrido et al., 2015). If the procedure was not successful (severe
damage like a full retinal detachment, lens opacity due to injury),
the mice were excluded from further analysis.
Functional Analysis by Ganzfeld
Electroretinography
Electroretinograms (ERGs) were recorded according to the
previously described procedures (Tanimoto et al., 2009). The
ERG system consisted of a xenon light source, a Ganzfeld bowl, a
signal amplification system (band-pass 0.3–300 Hz), a PC-based
control and recording unit, and a monitor (Multiliner Vision;
VIASYS Healthcare GmbH, Hoechberg, Germany). Animals
were dark adapted overnight, anesthetized and pupils were
dilated as described in section “subretinal AAV injections.” Single
flash intensity series data were obtained under photopic (light-
adapted 10 min at 30 cd/m2) conditions. Flash stimuli ranged
from−2.0 to 1.5 log cd∗s/m2 divided into ten steps. Responses to
trains of brief flashes (flicker) of fixed luminance (1 log cd∗s/m2)
but varying frequency (0.5, 1, 2, 3, 5, 7, and 10 Hz) were recorded
at the cornea under light-adapted conditions with a background
illumination of 30 cd/m2. Flicker responses were averaged either
20 times (for 0.5–3Hz) or 30 times (for 5–10Hz). Single flash
intensity and flicker frequency series data were obtained from
treated animals (one treated eye, one untreated eye) at indicated
time points after treatment.
Immunohistochemical Anaylsis
Vertical cryosections (10 µm) of the mouse retina were prepared
for immunohistochemical staining as described previously
(Michalakis et al., 2005). For an appropriate localization of the
treated and untreated retinal part, eyes were marked temporally
before harvesting. Antibodies used were rabbit anti-mouse
CNGA3 polyclonal antibody (Michalakis et al., 2005, applied
at 1:3,000 dilution) and rabbit anti-mouse S opsin polyclonal
antibody (Millipore, applied at 1:300 dilution). For secondary
detection donkey Cy3 anti-rabbit IgG was used (Jackson
ImmunoResearch). Cone photoreceptors were stained with
fluorescein isothiocyanate conjugated peanut agglutinin (FITC-
PNA; 1:100, Sigma-Aldrich). Confocal images were collected on
a LSM 510 (Carl Zeiss, Oberkochen, Germany) microscope.
Whole Mount Stainings
Animals were sacrificed, eyes were enucleated and immediately
fixed in buffered 4% paraformaldehyde for 10 min. For an
appropriate localization of the treated and untreated retinal
part, eyes were marked temporally before harvesting. For
immunostaining, retinal whole mounts were washed with 0.1M
PB (3× 10 min) and co-stained with FITC-PNA and rabbit anti-
mouse CNGA3 polyclonal antibody over night. For secondary
detection, a donkey Cy3 anti-rabbit IgG was used. After washing
with 0.1M PB the retinas were flat mounted on objective slides,
orientated and embedded in mowiol mounting medium. Pictures
were taken using a fluorescence microscope connected to a video
camera (Zeiss ApoTome, AxiocamMRm, Germany).
Statistical Analysis
In this study, two different types of Student’s t-tests were
used for statistical analysis to determine if two sets of data
are significantly different from each other. The independent
samples t-test (unpaired independent samples) was used when
two separate sets of independent and identically distributed
samples were obtained, one from each of the two populations
being compared were non-overlapping (e.g., when comparing
the effects of the two capsid variants). The paired t-test (paired
dependent samples) was used to when one group was tested on
Frontiers in Neuroscience | www.frontiersin.org 3 May 2017 | Volume 11 | Article 292
Mühlfriedel et al. AAV-Mediated Gene Therapy for ACHM2
two time consecutive points (e.g., repeated measurements at 1
and 12 months PI).
RESULTS
Subretinal Delivery of AAV Vectors and
In vivo Monitoring of the Injection
Procedure
Each animal received a single subretinal injection of AAV
vector in one eye, while the other eye remained untouched and
served as control. To minimize any possible damage due to the
surgical procedure a total volume of 1 µl AAV vector suspension
was injected. The technical outcome was monitored via in
vivo imaging of the mouse eye using confocal scanning-laser
ophthalmoscopy (cSLO) and spectral domain optical coherence
tomography (SD-OCT) within 10 min after subretinal delivery
of the AAV vector (Figure 1). Following the injection of 1 µl
vector suspension to the dorsal retina, a defined local subretinal
bleb became evident in cSLO fundus imaging (Figures 1A,B). A
higher magnification (10◦ field of view) revealed the trajectory of
retinal blood vessels at the border of the transitory subretinal bleb
(Figure 1C). Subsequent assessment of horizontal and vertical
SD-OCT scans confirmed the detachment of the retina from
the RPE at the subretinal bleb area (Figure 1D). This subretinal
detachment resolved spontaneously within a few days, and after
4 weeks only subtle morphological abnormalities around the
injection site and within the former detached area remained
detectable (Figures 1E–H).
To assess the extent of transduction obtained within the area
of the subretinal injection, we harvested the retina from mice
treated with a dose of ∼5 × 109 total vector genomes of AAV2/8
(Y733F)-S opsin-Cnga3, expressing murine Cnga3 under control
of the mouse S opsin promoter. After labeling with a specific
anti-CNGA3 antibody and the cone photoreceptor marker
peanut agglutinin (PNA), the retina was flat-mounted and
imaged under an epifluorescence microscope (Figures 2A–D).
As described earlier, the natural course of cone photoreceptor
degeneration in this model follows a ventral to dorsal gradient
(Michalakis et al., 2005). Consequently, at 4 months post-
injection (PI), only a few remaining cones were labeled by
the cone marker PNA in the ventral half (V) of the flat-
mounted Cnga3 KO retina (Figure 2A). Injections in this
set of experiments were placed in the ventral part, however,
transduction of the temporal or nasal parts of the retina due
to vector diffusion could not be excluded. Immunolabeling
confirmed the presence of mouse Cnga3 protein in the treated
part of the retina surrounding the injection site (Figure 2B).
The area of cone-specific expression of CNGA3 (red) following
the single subretinal injection spanned about 1/3 of the entire
retina. A closer inspection of the overlay of the Cnga3 expression
pattern with the PNA staining revealed a substantial number
of PNA-positive cones in the ventral half of the treated Cnga3
KO retina (Figures 2C,D). As this area normally lacks cones
at this stage of degeneration (Michalakis et al., 2005), one
can conclude that the extended cone survival is related to the
treatment.
FIGURE 1 | Monitoring of retinal integrity after subretinal AAV delivery. (A–H) In vivo cSLO and SD-OCT scans of the subretinal bleb 10 min (A–D) and 4
weeks (E–H) after injection at PM1. The dashed line indicates the area of the bleb due to subretinal detachment, arrows mark the injection site. A total volume of 1.0
µl AAV 2/8 (Y733F)-S opsin-Cnga3 was injected into the dorsal-temporal part of the retina. d, dorsal; n, nasal; t, temporal; v, ventral; onh, optic nerve head. GCL,
ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner segments; OS, outer segments;
RPE, retinal pigment epithelium; CC, choroid complex.
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FIGURE 2 | Immunolabeling of flat-mounted treated Cnga3 KO retina. (A–D) Representative montage images of epifluorenscence imaging of a treated Cnga3
KO retina mounted with the photoreceptor side up. The animal was treated at the age of 2 weeks with AAV2/8 (Y733F)-S opsin-Cnga3 and imaged at 4 months after
treatment. (A) Cones were stained with the marker peanut agglutinin (PNA, green). In 4-month-old Cnga3 KO mice, the majority of ventrally located cones, specifically
of blue opsin expressing (S opsin) cones, are lost in untreated regions. (B) Immunosignal obtained with a Cnga3-specific antibody (red) revealed that about 1/3 of the
treated Cnga3 KO retina was transduced with a single injection and expressed the AAV vector-encoded Cnga3 protein. (C) Merged image showing an overlay of
Cnga3 (red) and PNA (green) signals. (D) Magnified detail of the treated area as shown in (C). d, dorsal; n, nasal; t, temporal; v, ventral; onh, optic nerve head.
Therapeutic Capacity of Two Different
Modified Capsids AAV2/5 (Y719f) and
AAV2/8 (Y733f)
To evaluate potential differences in the therapeutic capacity of
two different modified pseudotyped AAV2 vectors expressing
mouse Cnga3 cDNA (AAV2/5 Y719F and AAV2/8 Y733F),
we compared the outcome in two groups of respectively
treated Cnga3 KO mice for a period of up to 3 months PI.
Retinal function was assessed via Ganzfeld ERG to investigate
the contribution of the rod and the cone system (Figure 3).
Figure 3A shows a comparison of wild-type (wt) mouse data to
the ERGs of the AAV2/8 (Y733F)-treated and untreated eyes of
a Cnga3 KO animal. Under scotopic (dark-adapted) conditions,
the specific rod system response (Figure 3A, top) revealed no
difference between the treated eye (TE, red traces), untreated eye
(UE, black traces), and the wild-type (wt) eye (gray traces). This
finding indicates that the injection procedure had no measurable
deleterious effects on retinal functionality, and corroborates the
published data for AAV2/5 (Y719F) (Michalakis et al., 2010).
Use of a more intense flash under scotopic conditions [ISCEV
standard flash, Marmor et al., 2004], which potentially evokes
mixed rod/cone system responses, revealed a higher b-wave
amplitude in the TE relative to the UE, indicating a contribution
of the cone system (Figure 3A, lower part of top graph). Cone
function may usually best be observed under photopic, light
adapted conditions, as in the bottom graph of Figure 3A. The
respective photopic single flash recording clearly shows the
treatment effect on cones in the TE, while there is merely a
zero baseline in the UE. Again, these results in AAV2/8 (Y733F)
corroborate the published data for AAV2/5 (Y719F) (Michalakis
et al., 2010), including the fact that the approximate size of the
treated area of 1/3 of the retina corresponds to an ERG amplitude
of 1/3 to 1/4 of wt.
A particularly valuable biomarker for cone function is the
photopic flicker ERG. For the direct comparison between
AAV2/5 (Y719F) and AAV2/8 (Y733F), we chose a flash
frequency of 7 Hz (Figure 3B). The presence of three consecutive
flash responses in a trace enhances the visibility of differences and
the detection of potential rescue effects. In general, Figure 3B
again clearly shows the benefit of the intervention on cone
functionality for both serotypes, and for both observation
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FIGURE 3 | Functional performances of AAV2/5 (Y719F) and AAV2/8 (Y733F) vector serotypes in vivo. (A–C) Cnga3 KO mice were treated at an age of 2
weeks with AAV2/5 (Y719F)- or AAV2/8 (Y733F)-S opsin-Cnga3 vectors and the functional outcome was assessed at 1 and 3 months PI. (A) Representative single
flash ERG traces obtained under scotopic (dark-adapted) or photopic (light-adapted) conditions. Top traces: scotopic rod system response, center traces: scotopic
mixed rod/cone system response, bottom traces: photopic cone system response. (B) Comparison of photopic 7 Hz flicker ERG responses obtained from
representative animals treated with AAV2/5 (Y719F) or AAV2/8 (Y733F) serotypes. Top panel: evaluation at PM1 PI, bottom panel: evaluation at PM3 PI. (C) Box plots
summarizing the corresponding group data (n = 10). ERG b-wave amplitudes of TEs are shown in red and those of UEs in black. Boxes indicate the 25–75% quantile
range, whiskers the 5 and 95% quantiles and solid lines connect the medians of the data. As no flicker waveform could be detected in any of the UEs, the result are
indicated as “n.d.” (non-detectable). SF, single flash.
intervals at 1M and 3M post-injection (PI). Due to the complete
lack of both cone (Cnga3 KO) and rod responses (which
were desensitized with background light), the UEs are unable
to respond, while there are distinct responses in the TEs
(Figure 3B). We found no visible differences in cone system
functionality between the AAV2/5 (Y719F) and the AAV2/8
(Y733F) groups, neither in the waveforms (representative traces
in Figure 3B) nor in the group amplitude data (box plots)
summarizing the results at 1M and 3M PI for each serotype
(Figure 3C). The traces of the UEs did not contain any
discernible waveforms, so that no amplitudes weremeasurable, as
marked by “n.d.” for “non-detectable” in Figure 3C. A statistical
work-up of the data summarized in Figure 3C revealed
(a) no differences between AAV2/5 (Y719F) and AAV2/8
(Y733F) at 1M (p= 0.94) and 3M (p= 0.75),
(b) no differences between AAV2/5 (Y719F) at 1M and AAV2/5
(Y719F) at 3M (p= 0.21), and
(c) no differences between AAV2/8 (Y733F) at 1M and AAV2/8
(Y733F) at 3M (p= 0.64).
As (b) and (c) involve follow-up data from the same individual
animals, a paired t-test was applicable, while an unpaired t-test
was used in (a) as the data originate from different mice. These
findings suggest that a robust rescue of the Cnga3 KO phenotype
was achieved over a 3 months period with both AAV vector
serotypes, AAV2/5 (Y719F) and AAV2/8 (Y733F).
Long-Term Performance of AAV-Mediated
Cnga3 Gene Supplementation Therapy
A key outcome of any gene supplementation therapy is a
sustained, optimally life-long rescue. Published data (Michalakis
et al., 2010) and the results shown above document a beneficial
effect of the treatment up to 3 months PI. Here, we investigated
the performance of the treatment over a period of 12 months
PI, as the average lifespan of mice does not permit longer
periods without unduly increasing the risk of systematic errors.
In these long-term experiments, the AAV2/5 (Y719F)-S opsin-
Cnga3 vector was used, and 1 µl subretinally injected into the
ventral retina of 2-week old Cnga3 KO mice. The functional
assessment of cone photoreceptor function was done at 1 M and
12 M PI (Figure 4A). Figures 4B,C summarizes the Ganzfeld
ERG recordings with a focus on the biomarker used in previous
sections (7 Hz photopic flicker ERG). For comparison to
Figure 3A, the results of the photopic single flash ERG are
included in Figure 4C. As illustrated in Figures 4B,D, cone-
mediated function persisted at a similar level over the entire
observation period of 12 months. Consequently, a statistical
analysis as described above based on the data summarized
in Figure 4D indicated no significant differences in treatment
effects (p = 0.5). This result is particularly encouraging as the
treated area covered parts of the ventral retina where, without
therapy, cones are completely lost after 4 months (Michalakis
et al., 2005), indicating that these targeted cones were saved.
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FIGURE 4 | Long-term outcome of AAV treatment. (A–D) Cnga3 KO mice
were treated with AAV2/5 (Y719F)-S opsin-Cnga3 and analyzed according to
the scheme depicted in (A). (B) Representative photopic (light-adapted) 7 Hz
flicker ERG traces obtained at 1M and 12M PI. (C) Photopic (light-adapted)
single flash ERG recordings from a treated (TE, red trace), untreated (UE, black
trace), and wild-type (wt) eye (gray trace) obtained at 12M PI. (D) Box plots
summarizing the corresponding flicker ERG group data (n = 14). Flicker ERG
amplitudes of TEs are shown in red and those of UEs in black. Boxes indicate
the 25–75% quantile range, whiskers the 5 and 95% quantiles and solid lines
connect the medians of the data. As no flicker waveform could be detected in
any of the UEs, the result are indicated as “n.d.” (non-detectable). PM, post
natal month; PI, post-injection. SF, single flash.
Upon completion of the ERG measurements, the retinas
were harvested for immunohistological analyses. We used the
cone marker PNA and a CNGA3-specific antibody on vertical
cryo-sections through the retina of treated Cnga3 KO mice. A
representative confocal overview image from a retinal section
including a treated (right) and untreated (left) area is shown in
Figure 5A. AAV vector-encoded CNGA3 protein is still clearly
detectable at 12 M PI in cones within the treated, but not in
the untreated part of the Cnga3 KO retina (Figure 5A). These
CNGA3-positive cones were also positive for the cone marker
PNA (Figure 5B) whereas only a few surviving CNGA3-negative
cones were found (see left, untreated part in Figure 5B). Higher
magnification images show that most of the CNGA3 protein
localized to cone outer segments, but some protein was also
observed in cone cell bodies and synapses (Figures 5C,D). S
opsin-positive cones are not found in untreated Cnga3 KO retina
older than 4 months of age (Michalakis et al., 2005). However,
S opsin-positive cones still survived at 12 M PI in the treated
ventral part of Cnga3 KO retina (Figure 5E), suggesting that
the treatment may halt degeneration of the fast degenerating S
opsin-positive cones.
Is the Therapy Still Effective When Applied
at More Advanced Stages of Disease?
Finally, we treated 3-month-old (PM3) Cnga3 KO mice in the
same way as before the 2-week-old animals, using the AAV2/8
(Y733F)-S opsin-Cnga3 vector (Figure 6A). Since the peak of
cone cell death is at about postnatal day 35 (Arango-Gonzalez
et al., 2014) and cone degeneration is particular present in the
ventral Cnga3 KO retina, we aimed at delivering the vector
entirely to the dorsal retina to target the slower degenerating
dorsal cones. We found that although presumably a substantial
number of cones has already been lost at time of treatment, it
was still possible to endow the remaining cones with the ability
to generate specific light responses (Figure 6B). The treatment
effect persisted up to 12 M PI (Figure 6B). The functional benefit
was confirmed by single flash ERG recordings (Figure 6C). In
summary, the preclinical results in Cnga3 KO mice show that
even at advanced stages of degeneration up to at least PM3,
surviving cones are still treatable.
DISCUSSION
Achromatopsia is a severely disabling inherited retinal disease
with a high clinical and socioeconomic importance. An estimated
80% of ACHM cases are caused by mutations in one of the two
genes encoding the cone CNG channel (CNGA3 and CNGB3).
In Europe and the United States, CNGB3mutations are found in
∼50% of patients, while CNGA3 mutations are found in about
30% of cases (Kohl et al., 2005). Mutations in all other known
ACHM genes together account for less than 6% of patients.
With the discovery of genetic causes of human diseases, the
creation of homologous animal models and the development
of efficient gene transfer strategies for these previously non-
treatable disorders became feasible. So far, several groups have
focused on developing gene therapies for CNGA3 or CNGB3
(Michalakis et al., 2017). This includes a number of pivotal proof-
of-concept studies forCNGA3 andCNGB3 gene supplementation
in mouse models (Michalakis et al., 2010; Carvalho et al.,
2011; Pang et al., 2012), dog models (Komaromy et al., 2010,
2013), or sheep models of ACHM (Banin et al., 2015). All
studies utilized AAV vectors and indicated that supplementation
of the missing gene product was able to rescue the ACHM
phenotype. A particular asset of therapy in ACHM is that
it enables previously non-functional cone photoreceptors to
generate specific light responses reminiscent of normal cone
responses. These encouraging results triggered the initiation of
translational projects aiming at the transfer of such AAV-based
gene supplementation treatments for ACHM into the clinics
(Michalakis et al., 2017). However, the challenges of human gene
supplementation therapy are multifaceted. They comprise the
necessity to fully understand the etiopathology of the targeted
disease and its genetic mechanisms.
In the present study, three important facts in the murine
Cnga3 gene supplementation became apparent:
(i) The functional restoration of the deficient murine cone
system was independent of the two AAV serotypes used,
AAV2/5 (Y719F) and AAV2/8 (Y733F). This is an important
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FIGURE 5 | Immunohistological evaluation of an AAV-treated Cnga3 KO retina at 12M PI. (A–E) Representative confocal scans of vertical cryo-sections
obtained from the retina of Cnga3 KO mice at 12 months (12M) after treatment with AAV2/5 (Y719F)-S opsin-Cnga3. Staining was performed using specific
antibodies and the cone-specific marker peanut agglutinin (PNA). Cell nuclei were marked with Hoechst 33342. (A–D) Low magnification survey (A,B) and high
magnification detail images (C,D) featuring Cnga3 immunosignal (red) alone (A,C) or in combination with the PNA signal (green) (B,D). The region depicted in (A,B)
spans from the treated (right) to the untreated (left) part of the retina. (C,D) shows higher magnification details from the treated part. (E) Overview image from a
consecutive cryo-section to the section shown in (A,B) stained with an S opsin-specific antibody. The S opsin signal (green) indicates preservation of this subtype of
cones at 12M PI.
finding due to the fact that each AAV serotype shows
unique transduction characteristics (Sanlioglu et al., 2001).
In particular, the AAV serotypes’ ability to transduce
cones has been evaluated in the pig (Manfredi et al.,
2013) and non-human primate (Vandenberghe et al., 2013)
retinas, which present cone density and distribution more
similar to humans than mice. Among these, serotypes
AAV2/5 (Alexander et al., 2007; Mancuso et al., 2009;
Komaromy et al., 2010), AAV2/8 (Manfredi et al., 2013),
and AAV2/9 (Vandenberghe et al., 2013) were found
to present the highest cone transduction properties. In
addition to the large portfolio of naturally-occurring
AAV serotypes, novel AAV capsid variants with enhanced
gene transfer efficiency and altered tropism have been
generated in recent years (Vandenberghe et al., 2009).
Phosphorylation of specific tyrosine residues within the
AAV capsid is thought to be responsible for AAV targeting
to proteasome and degradation (Zhong et al., 2008).
Therefore, the exchange of conserved tyrosine residues
with phenylalanine in AAV capsids of different serotypes
results in higher levels of transduction compared to wild-
type AAV capsids, presumably allowing AAV particles to
escape the proteasome and reach the nucleus. In particular,
AAV2 (Y444F), AAV2 (Y730F), AAV8 (Y733F), and AAV9
(Y446F) have an efficacy similar to that of wild-type AAV
at lower doses, a broader tropism within the neuronal
retina and enhanced diffusion across the retina (Petrs-
Silva et al., 2009). Our data reveal the efficacy of the
treatment of Cnga3-deficiency by using two modified
capsids, AAV2/5 (Y719F) and AAV2/8 (Y733F) thereby
confirming these findings as described in the literature.
While we describe here, for the first time, a stable treatment
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FIGURE 6 | Dependency of AAV treatment on age at intervention. (A–C)
Cnga3 KO mice (n = 4) were treated with AAV2/8 (Y733F)-S opsin-Cnga3 and
analyzed according to the scheme depicted in (A). (B) Representative
photopic (light-adapted) 7 Hz flicker ERG traces obtained at 1M and 12M PI
when treated at PM3. (C) Photopic (light-adapted) single flash ERG recordings
from a PM3-treated (TE, red trace), untreated (UE, black trace), and wild-type
(wt) eye (gray trace) obtained at 12M PI. PM, postnatal month; PI,
post-injection. SF, single flash.
effect using the AAV2/5 (Y719F) variant, the AAV2/8
(Y733F) variant has been successfully used to drive long-
term expression of PDE6B and improvement of the retinal
phenotype in rd10 mice, a model of autosomal recessive RP,
which is challenging due to the aggressive and severe PR
degeneration (Pang et al., 2011).
(ii) The general aim of viral vector-mediated gene
supplementation therapy of inherited disorders is to
provide long-term beneficial effects optimally after a single
treatment. Therefore, it is always critical to assess the
duration of the treatment effect in a relevant model. For
CNGB3-linked ACHM long-term follow-up studies (up to
42 months) after Cngb3 supplementation in the Cngb3-
deficient dog model have been published (Komaromy et al.,
2010, 2013). For CNGA3-linked ACHM such long-term
data were missing so far. Here, we show for the first time
that AAV-mediated Cnga3 gene supplementation in young
treated Cnga3 KO mice results in long-term, presumably
lifelong beneficial effects on cone-mediated function for at
least 12 months after treatment. At late time points beyond
12 months of age in mice, the treatment effect may become
diminished due to natural aging. Because of the shorter
life span and different metabolism of mice (Dutta and
Sengupta, 2016), this range corresponds to a considerably
high age in humans. Since we were lacking a cohort of
wild-type mice tested under the same conditions and in the
same intervals, the generation of a reference baseline for
natural aging remains to be established in future work.
(iii) As on one hand many hereditary eye diseases like RP are
often diagnosed at advanced disease stages or on the other
hand the pathology in some forms develops already before
birth or very early in life, a curative gene therapy approach
may come too late to efficiently tackle the degeneration
process. Thus, it is of paramount importance to ascertain
the therapeutic time window for efficient gene delivery in
each disease. Here, we show that 3-month-old Cnga3 KO
mice may still be successfully treated. We were further
able to confirm that this effect persisted for at least 12
months post-injection. This is remarkably given that the
absolute age of the treated Cnga3 KO mice in this case
was 15 months and significant cell death and loss of cone
photoreceptors can be observed in the Cnga3 KO retina
already at the age of 3 months (Michalakis et al., 2005;
Arango-Gonzalez et al., 2014). At these advanced stages of
the disease cone photoreceptors are barely detectable in the
ventral half of the untreated Cnga3 KO retina (see Figure 2
and Michalakis et al., 2005, 2010; Arango-Gonzalez et al.,
2014). Importantly, the finding that we were still able to
rescue the ACHM phenotype in 3-month-old Cnga3 KO
mice suggest a rather wide therapeutic time window of
opportunity.
In conclusion, we found that AAV-mediated Cnga3 gene
supplementation therapy was effective with both AAV2/5
(Y719F) and AAV2/8 (Y733F) capsid serotypes in Cnga3 KO
mice. Our long-term data indicate a persistence of the treatment
effect for an observational period of 12M PI even when
applied at an advanced stage of cone degeneration at least
up to PM3. These results hold promise for respective clinical
trials in ACHM patients (e.g., clinical trials.gov identifiers:
NCT02610582, NCT02599922, and NCT03001310). Given that
mice lack a macula it is hard to extrapolate the present
data and predict the outcome of clinical studies on ACHM.
However, based on our findings, we can assume that even
small, cone-rich areas in the macula are a valuable target for
gene supplementation. Further studies have to clarify how many
cones have to persist for a successful therapy. Our findings
further suggest that sizable time windows for the efficient
application of gene therapy may be available in a broader
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spectrum of gene-therapeutic approaches of hereditary eye
diseases.
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